Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome
Sponsor: Tanta University
Summary
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, with insulin resistance playing a central role in its pathophysiology. Hyperinsulinemia can enhance ovarian androgen production and reduce hepatic sex hormone-binding globulin synthesis, thereby aggravating hyperandrogenism and reproductive abnormalities. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances endogenous incretin activity and may improve insulin sensitivity and glucose homeostasis. Emerging evidence suggests that DPP-4 inhibition may also influence body weight, androgen excess, inflammation, and reproductive function in women with PCOS.
Official title: Efficacy and Safety of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome
Key Details
Gender
FEMALE
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2026-09-20
Completion Date
2027-03-30
Last Updated
2026-09-21
Healthy Volunteers
No
Conditions
Interventions
Metformin
Metformin is a widely used insulin-sensitizing agent and one of the most established pharmacological treatments for the metabolic abnormalities associated with polycystic ovary syndrome
Vildagliptin (Galvus)
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances endogenous incretin activity and may improve insulin sensitivity and glucose homeostasis.